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In this study we have applied epitope excision and epitope extraction strategies, combined
with matrix assisted laser desorption/ionization mass spectrometry, to determine the fine
structure of epitopes recognized by a polyclonal antibody to human immunodeficiency virus
envelope glycoprotein gp120. This is the first application of this approach to epitope mapping
on a large, heavily glycosylated protein. In the epitope excision method, gp120 in the native
form is first bound to the antibody immobilized on sepharose beads and cleaved with
endoproteinase enzymes. In the epitope extraction method, the gp120 was first proteolytically
cleaved and then allowed to react with the immobilized antibody. The fragments that remain
bound to the antibody, after repeated washing to remove the unbound peptides, contain the
antigenic region that is recognized by the antibody, and the bound peptides in both methods
can be characterized by direct analysis of the immobilized antibody by matrix assisted laser
desorption ionization/mass spectrometry. In this study we have carried out epitope excision
and extraction experiments with three different enzymes and have identified residues 472–478
as a major epitope. In addition, antigenic regions containing minor epitopes have also been
identified. (J Am Soc Mass Spectrom 1998, 9, 157–165)
The initial step in the entry of human immunode-ficiency virus type 1 (HIV-1) into the target cell isthe binding of exterior envelope glycoprotein
gp120 to the human cellular receptor CD4 [1]. Subse-
quently, gp120 mediates the fusion of viral and host
membranes to facilitate the entry of the virus into the
host cell [2]. The envelope glycoprotein gp120 is syn-
thesized as a gp160 precursor and cleaved intracellu-
larly into gp120 and gp41 [3, 4]. The gp120 contains
about 480 amino acids, and approximately half of its
apparent molecular weight is attributed to N-linked
complex and high mannose/hybrid carbohydrate
chains [5].
Sequence comparison of different HIV-1 isolates and
biochemical studies have shown that gp120 contains
five conserved domains (C1–C5) and five variable do-
mains interspersed on a complex loop structure formed
by nine intramolecular disulfide bonds [6–8]. The CD4
binding region in gp120 has been defined as a discon-
tinuous region involving C3 and C4 domains [9–11].
HIV gp120 has received the most attention as a
potential vaccine against HIV infection because gp120
elicits most of the neutralizing antibodies found in sera
of infected patients [3]. The conserved CD4 binding
region and the variable loop V3 have been shown as the
two major domains recognized by neutralizing antibod-
ies [12–14]. Experiments in chimpanzees have shown
that vaccination with gp120 and its subunits (V3 pep-
tide) provides protective immunity against HIV-1 infec-
tion [15–17]. Although gp120 vaccination of human
volunteers has been shown to elicit neutralizing anti-
bodies in sera, protection against infection has been
questioned [18, 19]. The success of gp120 based vaccine
is, therefore, dependent on identifying the components
of gp120 associated immune responses in humans,
characterizing the effects of these antibodies on the
infectious pathway and characterizing the molecular
mechanism by which the virus in neutralized. Epitope
mapping is an integral part of the studies to identify the
antigenic region(s) of gp120 recognized by the neutral-
izing and non-neutralizing antibodies in sera.
The most common approaches to epitope mapping
are peptide binding and fine-specificity analysis by
using native and recombinant proteins, proteolytic frag-
ments, synthetic peptides, and site-directed mutants.
Proteolytic footprinting method of epitope mapping
was first proposed by Jemmerson and Patterson based
Address reprint requests to Dr. Kenneth B. Tomer, National Institute of
Environmental Health Sciences, P.O. Box 12233, Research Triangle Park, NC
27709. E-mail: tomer@niehs.nih.gov
* Laboratory of Signal Transduction.
Published by Elsevier Science Inc. Received July 10, 1997
1044-0305/98/$19.00 Revised September 30, 1997
PII S1044-0305(97)00247-X Accepted October 6, 1997
on the resistance of the antigenic region to proteolytic
cleavage when it is bound to the antibody [20]. In this
approach, the antigen of interest is first complexed with
an antibody and then digested with proteolytic en-
zymes. The peptide fragments that contain the epitope
remain bound to the antibody and the nonantigenic
fragments become free from the immunocomplex. The
unbound nonantigenic fragments are separated by
HPLC and the bound peptides are identified by com-
paring the chromatographic profiles of the enzymatic
digest in the presence and absence of antibody. Przy-
bylski and co-workers combined the proteolytic foot-
printing method with plasma desorption ionization
mass spectrometric characterization of peptides to map
an epitope recognized by a monoclonal antibody [21].
In this study the separation of antigenic peptides was
simplified by using immobilized antibodies where the
antigenic peptides remain bound while the unbound
nonepitope peptides were simply washed off after the
proteolysis. However, the need to elute and purify the
bound antigenic fragments before the mass spectromet-
ric characterization was a limitation on this method.
The proteolytic footprinting method has also been
termed epitope excision [22]. Because the antigen is
bound to the antibody in the native state, epitope
excision can be applied to the mapping of continuous
and discontinuous epitopes.
An alternate approach, epitope extraction, has also
been proposed to characterize the antigenic fragments
in a mixture of proteolytic peptides [22]. In this study
the antigen is first proteolytically cleaved and the
resulting solution is allowed to react with the antibody.
The peptides that contain the epitope bind to the
antibody whereas the nonbound peptides remain in the
supernatant and can be filtered off. Only continuous
epitopes can be mapped by epitope extraction.
Our laboratory has shown that antigenic fragments
bound to an immobilized antibody can be directly
analyzed by matrix assisted laser desorption ioniza-
tion/time of flight/mass spectrometry (MALDI/TOF/
MS) without eluting them from the antibody [23]. In the
direct analysis method, a small amount of antibody
beads are cocrystallized with the matrix directly on the
sample plate and analyzed by MALDI/MS. Because the
antibody is covalently bound to the solid matrix, only
affinity-bound peptides are desorbed during the
MALDI process. The peptides can be identified by
matching the masses of the fragment to the predicted
peptide masses.
The potential of MALDI/MS to characterize affinity-
bound peptides has increasingly been applied in
epitope mapping. An additional advantage of the direct
analysis is that several consecutive enzymatic reactions
can be carried out on the bound fragments permitting a
finer determination of the epitope [24]. A continuous
epitope on HIV-1IIIB p26 recognized by a mouse mono-
clonal antibody has recently been identified by combin-
ing the proteolytic footprinting method with direct
analysis of bound peptides [25].
An alternate method has been employed by Chait
and co-workers based on immunoprecipitation of pro-
teolytically cleaved proteins or synthetic peptides [26,
27]. The affinity bound peptides have been character-
ized by MALDI/MS after complexing the antigenic
peptide-antibody complex with protein G/protein
sepharose beads. In another approach, Przybylski and
co-workers have used a nonimmobilized antibody in
the epitope excision and epitope extraction methodolo-
gies to identify an epitope on a 32 amino acid (aa)
peptide derived form heart muscle protein troponin T
[28]. In this study, the immunocomplex was separated
from the nonbound peptides by filtration through mi-
croconcentrators with the bound peptides being eluted
from the antibody before MALDI/MS analysis.
Epitopes on proteins with molecular weight .30,000 or
on glycosylated proteins, however, have not been
probed by these methodologies.
To study the applicability of epitope excision and
epitope extraction methodologies to HIV-1 envelope
glycoprotein gp120, we have applied them to the inves-
tigation of epitopes on recombinant gp120 from HIV-
1SF2 (Mr ;100,000), which are recognized by a limited
polyclonal antibody (i.e., raised against a peptide en-
compassing a limited part of the protein’s amino acid
sequence). This study is the first application of these
techniques to a large, highly glycosylated protein under
native conditions. The characterization of the multiple
epitopes within the antigenic domain recognized by the
polyclonal antibody would provide information about
the immunodominant epitope that elicits the strongest
antigenic response. In addition to validating the appli-
cability of these techniques to probe linear epitopes, we
have also examined the applicability of the epitope
excision method to the characterization of the discon-
tinuous epitopes of gp120. Because intact gp120 is
bound to the polyclonal antibody under native condi-
tions, proteolytic cleavages are expected to result in the
binding of multiple antigenic peptides.
Experimental
Materials
HIV-1SF2 gp120 was obtained through the AIDS Re-
search and Reference Reagent program, division of
AIDS, NIAID, NIH, from Dr. Kathelyn Steimer, Chiron
Corporation. The glycosylated gp120 containing the
entire gene sequence (Glu31-Arg509) without the leader
sequence was expressed in CHO cells [29]. The sheep
anti-human immunodeficiency virus gp120 was ob-
tained from International Enzymes Inc. This antibody
was produced by first immunizing sheep with a syn-
thetic peptide that has the aa sequence APTKARRV-
VQREKR (497–511 in the envelope gene gp120 of the
BH10 strain of HIV-1) [30]. The antibodies were then
isolated from the sheep hyperimmune serum by affinity
chromatography by using the above synthetic peptide
coupled to sepharose.
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The enzymes Glu-C, Asp-N, and carboxypeptidase P
were purchased from Boehringer Mannheim (Indianap-
olis, IN) and Lys-C was purchased from Wako Chemi-
cal Co. (Dallas, TX). Leucine aminopeptidase was pur-
chased from Sigma Chemical Co. (St. Louis, MO). The
CNBr activated sepharose beads were purchased from
Pharmacia Biotech (Piscatway, NJ) and the a-cyano-4-
hydroxycinnamic acid was purchased from Aldrich
Chemical Co. (Milwaukee, WI). All other chemicals
were purchased from Sigma Chemical Co.
Preparation of CNBr Activated Sepharose-
Immobilized Antibody Beads
The CNBr activated sepharose beads were prepared
according to the manufacturer’s instructions. The dry
beads (1 mg) were suspended in 1 mM HCl and washed
repeatedly with 1-mM HCl. This procedure yields ap-
proximately 3.5 mL of slurried beads per mg of dry
beads. The sepharose beads were mixed with antibody
(1 mg per mL of slurried beads) that was dissolved in
coupling buffer 0.1-M NaHCO3, pH 8.3, and incubated
at room temperature for 1 h with gentle rotation. After
removing the excess antibody by washing with cou-
pling buffer, the unreacted sites were blocked with 0.1-
M Tris-HCl, pH 8.0. The beads were again washed with
alternating pH buffers pH 4.0 and pH 8.0.
Affinity Binding of gp120 to Immobilized Antibody
and Proteolytic Footprinting (Epitope Excision)
The immobilized Ab beads were equilibrated with
phosphate buffered saline (PBS) in a mini-reaction
column and was allowed to react with gp120 (1 mg/
mL) for 2 h at room temperature with gentle rotation.
After removing the supernatant, the antibody beads
were washed with PBS to remove excess gp120. The
affinity bound gp120 was digested separately with
enzymes Glu-C, Asp-N, or Lys-C. The beads were
equilibrated with 25-mM ammonium carbonate buffer,
pH 7.8; 50-mM sodium phosphate buffer, pH 8.0 and
25-mM Tris HCl buffer, 1-mM EDTA, pH 8.5, respec-
tively, for the Glu-C, Asp-N, and Lys-C digestions. The
enzymes (1 mg/mL) were added to the bead slurry in a
1:20 enzyme to substrate volume ratio and incubated at
37°C for 4–8 h. The unbound products were removed
by washing with the appropriate buffer, and the affin-
ity-bound peptides were characterized by MALDI.
Epitope Extraction
The gp120 (1 mg/mL) was diluted with equal volumes
of 50-mM ammonium carbonate, pH 7.8, 100-mM so-
dium phosphate buffer, pH 8.0 or 50-mM Tris HCl, 2
mM EDTA, pH 8.5 for Glu-C, Asp-N, and Lys-C diges-
tions, respectively. The enzymes were added in a 1:30
enzyme:substrate ratio and incubated for 6–12 h at 37°C
with gentle rotation. The immobilized Ab beads were
equilibrated with the appropriate digestion buffer,
mixed with the resulting gp120-digests, and incubated
for another 1 h at room temperature. The unbound
peptides and the enzyme were removed by washing the
beads with the digestion buffer three times, and the
peptides affinity bound to the antibody beads were
characterized by MALDI.
Leucine Aminopeptidase Digestion
The immobilized antibody beads containing the affini-
ty-bound peptides were equilibrated with 100-mM
phosphate, pH 7.0 and leucine aminopeptidase (1 mg/
mL) was added at an enzyme:substrate ratio of 1:10 to
1:5 and digested overnight. The reaction progress was
checked by taking aliquots at 1 h intervals. The beads
were then washed with the digestion buffer and char-
acterized by MALDI.
Carboxypeptidase Digestion
The immobilized antibody beads containing the affini-
ty-bound peptides were equilibrated with 50-mM am-
monium acetate, pH 4.5, and carboxy peptidase was
added in a 1:3 ratio. Aliquots were taken for MALDI
characterization at 1-, 2-, 5-, 10-, and 30-min intervals.
The rest of the beads were washed with the digestion
buffer and characterized by MALDI.
MALDI–Mass Spectrometry
The MALDI/TOF analyses were performed on a Voy-
ager-RP (PerSeptive Biosystems, Framingham, MA)
equipped with a video camera that displays a real time
image on a monitor. A 337-nm nitrogen laser was used
to desorb/ionize the samples. The acceleration voltage
was 30 kV. An external mass calibration was used with
known peptides. For the sample preparation, 1 mL of
the affinity beads or the digest were placed on a
stainless steel target followed by 1-mL matrix and
allowed dry at room temperature. A saturated solution
of recrystallized a-cyano-4-hydroxy cinnamic acid in
45:45:10 ethanol:water:formic acid was used as the
matrix for all the samples.
Results and Discussions
Affinity Bound gp120
The MALDI mass spectrum of recombinant HIV-ISF2
gp120 affinity bound to immobilized polyclonal anti-
body (International Enzymes), obtained by incubating
gp120 with the antibody beads for an hour at room
temperature and washed to remove the unbound
gp120, is shown in Figure 1. A broad molecular ion
(M 1 H)1 and multiply charged ions (M 1 2H)21 and
(M 1 3H)31 of gp120 are observed in the mass spectrum
with the molecular mass centered at 101,195 Da. A
MALDI spectrum of gp120 obtained in solution prior to
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the binding also showed ions with similar molecular
masses (data not shown). The average molecular mass
observed for gp120 here is approximately double the
molecular mass, 54,031 Da, of the polypeptide core of
HIV-1SF2 gp120 shown in Figure 2 [30]. The amino acid
residues of recombinant gp120 (rgp120) (Glu31-Arg509)
without the leader sequence are numbered from 1 to
479 in Figure 2 and the same numbering format will be
used throughout the article.
In a recent MALDI study, the molecular mass of a
recombinant gp120 from HIV-1 isolate GB8, was re-
ported as 92,000 Da [31]. The apparent molecular
weight determined by SDS-PAGE for gp120 from HIV-1
isolate GB8 was 112,000 Da. The discrepancy between
the MALDI/MS and SDS data has been attributed to the
anomalous behavior of glycosylated gp120 during SDS-
PAGE analysis. A detailed study on gp120 from HIV-
1IIIB, has shown that all of the 24 potential N-glycosyl-
ation sites are glycosylated with either complex or high
mannose/hybrid sugars [8]. The gp120 from HIV-1SF2
contains 26 potential N-linked glycosylation sites con-
taining the sequence N-X-S/T. The slightly higher av-
erage molecular mass observed in our present study
compared with that of gp120 from HIV-1 isolate GB8
can probably be accounted for by additional glycosyla-
tion sites, strain specific variation in the primary se-
quence, and by variations in the type of carbohydrate
moiety.
Epitope Excision and Extraction
The polyclonal antibody used in this study was raised
against a known antigenic region, a 15 amino acid
synthetic peptide corresponding to the highly con-
served C-terminal residues APTKAKRRVVQREKR of
gp120, and was affinity purified by using the same
peptide. The antigenic region is therefore expected to
contain several epitopes recognized by the individual
antibodies, the sequences of which are contained within
the primary sequence of the synthetic peptide.
A set of epitope excision and extraction experiments
were carried out with each of the endoproteinase en-
zymes Asp-N, Glu-C (from Staphylococcus Aureus V8),
and Lys-C.
Endoproteinase Asp-N Digestions
In the epitope excision experiment, gp120 affinity
bound to the immobilized antibody was digested with
Asp-N and washed to remove the nonbound fragments.
The direct analysis of the immobilized antibody by
MALDI/MS showed several peptides remaining bound
to the antibody (Figure 3a). The masses of the affinity-
bound peptides and the corresponding sequences are
listed in Table 1. The mass differences between the
observed and theoretical masses of the affinity-bound
peptides are within 0.1%. The mass of the most abun-
dant ion m/z 3988, corresponds to the sequence
DNWRSELYKYKVIKIEPLGIAPTKAKRRVVQRE (aa
445–477) of a peptide D189 resulting from the loss of
C-terminal residues K and R from peptide D18 (aa
445–479, m/z 4271). The peptide D18 is the C-terminal
peptide of gp120 predicted from the potential Asp-N
cleavage sites on gp120. In addition, a series of peptides
resulting from the truncation of additional C-terminal
residues E, R, QV, and V were also observed in the mass
spectrum. Further, the mass spectrum showed three
ions at m/z 3328, m/z 2795, and m/z 2503 whose
masses correspond to peptides D189a (aa 450–477)
D189b (aa 454–477), and D189d (aa 456–477) missing
residues DNWRS, DNWRSEL, and DNWRSELYKYK,
respectively, from the N-terminus of peptide D189. The
peptide D189a appears to result from a cleavage at
glutamyl residue 450 and the peptides D189b and D189d
appear to result from anomalous cleavages at tyrosine
454 and valine 467. The low abundant ions at ,2000
mass range represent multiply charged ions. The pep-
tide D189 and the anomalously cleaved peptides all
contain the residues of the synthetic peptide APTKAK-
RRVVQREKR that was used to raise the polyclonal
antibody, with the exception of the residues K and R.
Figure 1. MALDI mass spectra of gp120 from HIV-1SF2, affinity
bound to immobilized polyclonal antibody, showing singly and
multiply charged ions.
Figure 2. Amino acid sequence of envelope protein recombinant
gp120 from HIV-1SF2, without the leader sequence (Glu31-
Arg509), numbered from 1–479. The residues that are underlined
represent the primary sequence of the synthetic antigenic peptide.
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The primary sequence of all of the Asp-N peptides
recognized by the antibody can be mapped to a specific
sequence (aa 445–477) of gp120 from the C-terminal
domain.
Upon epitope extraction, when the Asp-N digest of
free gp120 was reacted with the immobilized antibody,
peptides D189 (aa 445–477 m/z 3987) and D189a (aa
450–477, m/z 3328) and truncated peptides resulting
from the loss of E, R, QV, and V from both of these
peptides were observed to bind to the antibody beads
(Figure 3b). In addition, an anomalously cleaved pep-
tide D189c (aa 455–477, m/z 2631) was also observed in
the mass spectrum. Some multiply charged ions of
affinity-bound peptides can also be observed in the
mass spectra at m/z ,2000. Thus, the Asp-N data
suggest that the epitopes recognized by the polyclonal
antibody is contained within the sequence aa 445–477
DNWRSELYKYKVIKIEPLGIAPTKAKRRVVORE).
It is important to note here that the peptide D18 (aa
445–479, m/z 4271), which contain all of the amino
acid residues of the synthetic peptide, was not observed
in the mass spectra of affinity bound peptides. The
failure to observe the C-terminal peptide D18 does not
exclude the residues K and R from the antigenic region,
as it was not observed in the digests of free gp120.
These results, however, indicate that C-terminal resi-
dues K and R are missing in this gp120 preparation. The
observation of truncated peptides missing residues E, R,
QV, and V in both the Asp-N and Glu-C experiments
show that further heterogeneity exists in the C-terminus
of gp120. Further digestions with leucine aminopepti-
dase and carboxypeptidase on affinity-bound peptide
D18 gave complex MALDI spectra that were difficult to
interpret because of the presence of the anomalously
cleaved peptides.
Endoproteinase Glu-C
In the epitope excision experiment, when affinity-
bound gp120 was digested with Glu-C, five peptides
were observed to remain bound to the antibody. The
most abundant ion (m/z 3199) corresponds to the mass
of the C-terminal peptide S21, LYKYKVIKIEPLGIAPT-
KAKRRVVQRE (aa 451–477) predicted from the poten-
tial Glu-C cleavage sites on gp120 (Figure 4a). The
masses of the remaining four peptides correspond to
the truncation of the C-terminal residues E, R, QV, and
V, respectively, from the peptide S21 (Table 1). Peptide
S21 contains all but the two C-terminal residues K and
R, of the synthetic peptide that was used to raise the
polyclonal antibody.
Figure 4b,c,d show the MALDI spectra of the Glu-C
digest of gp120 in solution prior to epitope extraction,
the peptides affinity bound to the immobilized anti-
body after the extraction, and the supernatant filtered
from the antibody beads, respectively. In Figure 4b, all
nonglycosylated peptides with masses above 600 Da are
observed except for S14 (S2 is a shoulder on S20). Figure
4c shows that peptide S21 and the truncated peptides
missing C-terminal residues E, R, QV, and V remain
bound to the antibody after the extraction. Comparing
the mass spectra in Figure 4b,d shows that all ions due
to peptide S21 and the truncated peptides in the solu-
tion digest have been removed by passing the solution
over the immobilized antibody. Figure 4c also shows a
minor peak corresponding to a disulfide-bonded pep-
tide S3 1 S4 (aa 18–34), binding to the antibody. The
peptide S3 1 S4 was also observed in the supernatant
indicating that its binding is not specific to the anti-
body.
To further define the epitope, peptide S21 still affin-
ity bound to the immobilized antibody was digested
with leucine aminopeptidase which cleaves N-terminal
residues except for X-P. After an overnight digestion,
loss of N-terminal residues LYKYKVIKI (aa 451–459)
from peptide S21 was observed. (A short digest is
shown in Figure 4e.) We note here that the peptides in
Figure 3e are 16 Da higher in mass than the predicted
peptide masses due to the oxidation of a single residue.
Longer digestions did not yield any further loss of
residues, probably due to the resistance of E-P to the
enzyme. These results further define the antigenic re-
gion to residues EPLGIAPTKAKRRVVQRE (460–477).
The binding of peptides missing C-terminal residues
E, R, QV, and V suggests that the epitopic region may
not include these residues. When digested with car-
boxypeptidase P, the peptide S21 and the truncated
Figure 3. MALDI mass spectra of (a) peptides affinity bound to
immobilized antibody upon epitope excision by Asp-N (the ions
marked with asterisks are the doubly charged ions of D189 and the
truncated peptides); (b) peptides affinity bound to immobilized
antibody upon epitope extraction of an Asp-N digest of gp120 in
solution (the ions marked with asterisks are the doubly charged
ions of D189a and D189a-E).
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peptides, however, showed no additional loss of C-
terminal residues. The resistance of these residues to
proteolysis indicates that these residues are, in fact,
involved in antigenic interactions with the polyclonal
antibody. Because the antibody is a polyclonal anti-
body, peptide S21 and each of the truncated peptides
may contain an epitope that does not include residues
E, R, QV, and V, respectively.
Endoproteinase Lys-C Digestions
The endoprotease Lys-C digestion was chosen to fur-
ther define the antigenic region because there are two
potential cleavage sites within the antigenic peptide
EPLGIAPTKAKRRVVQRE (aa 460–477) that remain
bound to the antibody after the aminopeptidase diges-
tion. Three peptides L27 (IEPLGIAPTK, aa 459–468),
L28 (AK, aa 469–470), and L29 (RRVVQREK, aa 471–
478) can be expected from the Lys-C digestion of free
gp120. Upon epitope excision, a peptide of m/z 943
and several other low intensity peaks of m/z 1071, 814,
1142, 2164, and at 2036 were observed in the
MALDI/MS spectra of affinity-bound peptides (Figure
5a). A mass of 943 corresponds to RRVVQRE (aa
471–477), L299 resulting from the loss of residue K from
peptide L29 (m/z 1070). The masses of the low abun-
dance ions correspond to L29 (aa 471–478), L299-E (aa
471–476), L28 1 L299 (aa 469–477), L27 1 L28 1 L299
(aa 460–477), and L27 1 L28 1 L299-E (aa 460–476),
respectively. A minor peak at m/z 2432 corresponding
to peptide L17 from the variable region V3 was also
observed in the mass spectrum. The aa sequence of L17
Table 1. The observed masses (m/z) of peptides affinity bound to immobilized antibody, obtained by direct analysis of MALDI/MS
after epitope excision and epitope extraction experiments with enzymes Asp-N, Glu-C, and Lys-C. Theoretical masses of the peptides
[(M 1 H)1] and the corresponding amino acid sequences are also shown
Observed mass
Peptide
Calculated
mass Position Amino acid sequence
Epitope
excision
Epitope
extraction
Endoproteinase
Asp-N
3988 3984 D189 3987 445–477 DNWRSELYKYKVIKIEPL
GIAPTKAKRRVVQRE
3858 3854 D189-E 3858 445–476 DNWRSELYKYKVIKIEPL
GIAPTKAKRRVVQR
3702 3698 D189-ER 3701 445–475 DNWRSELYKYKVIKIEPL
GIAPTKAKRRVVQ
3476 3471 D189-ERQV 3474 445–473 DNWRSELYKYKVIKIEPL
GIAPTKAKRRV
3375 3373 D189-ERQVV 3375 445–472 DNWRSELYKYKVIKIEPL
GIAPTKAKRR
3328 3326 D189a 3328 450–477 ELYKYKVIKIEPLGIAPTKA
KRRVVQRE
2795 D189b 2794 454–477 YKVIKIEPLGIAPTKAKRR
VVQRE
2632 D189c 2631 455–477 KVIKIEPLGIAPTKAKRRV
VQRE
2503 D189d 2503 456–477 VIKIEPLGIAPTKAKRRVV
QRE
Endoproteinase
Glu-C
3199 3199 S21 3199 451–477 LYKYKVIKIEPLGIAPTKA
KRRVVQRE
3070 3070 S21-E 3070 451–476 LYKYKVIKIEPLGIAPTKA
KRRVVQR
2914 2914 S21-ER 2914 451–475 LYKYKVIKIEPLGIAPTKA
KRRVVQ
2686 2686 S21-ERQV 2686 451–473 LYKYKVIKIEPLGIAPTKA
KRRV
2586 2587 S21-ERQVV 2587 451–472 LYKYKVIKIEPLGIAPTKA
KRR
Endoproteinase
Lys-C
2164 L(27 1 28 1 299) 2163 459–477 IEPLGIAPTKAKRRVVQRE
2035 L(27 1 28 1 299)-E 2033 459–476 IEPLGIAPTKAKRRVVQR
1142 L(28 1 299) 1142 469–477 AKRRVVQRE
1071 L29 1071 471–478 RRVVQREK
943 943 L299 943 471–477 RRVVQRE
814 814 L299-E 814 471–476 RRVVQR
2432 2429 L17 2430 279–300 SIYIGPGRAFHTTGRIIGD
IRK
1611 L2 1611 3–15 LWVTVYYGVPVWK
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has been verified by N-terminal and C-terminal ladder
sequencing with leucine amino peptidase and car-
boxypeptidase P.
Upon epitope extraction, when gp120 was digested
in solution with Lys-C and extracted with immobilized
antibody beads, the peptide L299 (aa 472–477, m/z 943)
was observed as a major peak and peptides L29 and
L29-E were observed as minor peaks (Figure 5b). In
addition, peptides L2 (aa 4–16, m/z 1611) from the
conserved region C1 and L17 (aa 279–300, m/z 2430)
were also observed in the MALDI spectrum. The pep-
tides L2 and L17 were also observed in the supernatant
after the epitope extraction (data not shown). Digesting
the peptide L299 affinity bound to the antibody beads
with carboxypeptidase P for several hours showed no
additional loss of residues and peptides L299 and L290
remained bound to the beads. Leucine aminopeptidase
failed to cleave any of the N-terminal residues from
L299. These results show that the major epitope recog-
nized by the antibody can be defined to residues
RRVVQRE (aa 471–477). The presence of peptide L299-E
(aa 471–476) and combination peptide L27 1 L28 1
L299-E in low abundance in the mass spectra suggest
that residues RRVVQR may also be defined as another
epitope of a less abundant paratope. The binding of
peptide L29, and combination peptides L28 1 L299,
L27 1 L28 1 L299, and L27 1 L28 1 L280 upon epitope
excision also suggests that additional epitopes may be
contained in these peptides. Peptides L27 (459–468) or
L27 1 L28 (459–470) were not observed to bind to the
antibody in the epitope excision or extraction experi-
ments. The absence of these peptides in the MALDI
spectrum indicates that the N-terminal residues of the
synthetic peptide APTKAK alone cannot be recognized
by the antibody. These residues may, however, be part
of the other overlapping epitopes.
As seen in the Asp-N experiments, neither the Lys-C
peptide L29 (RRVVQREK) predicted from the potential
cleavage sites of gp120 nor the combination peptide
L29 1 L30 (RRVVQREKR) were observed in the free
Figure 4. MALDI mass spectra of (a) peptides affinity bound to
immobilized antibody after epitope excision of gp120 with Glu-C
(b) Glu-C digest of gp120 in solution (c) affinity-bound peptides
extracted by the immobilized antibody beads from the Glu-C
digest of gp120 in solution (d) the supernatant containing the
unbound nonantigenic peptides after epitope extraction (e) affin-
ity-bound peptide S21 showing the cleavage of nonantigenic
N-terminal residues upon leucine aminopeptidase digestion.
Figure 5. MALDI mass spectra of (a) affinity-bound peptides
after epitope excision on gp120 affinity bound to immobilized
antibody by Lys-C (b) affinity-bound peptides extracted with
immobilized antibody from a Lys-C digest of gp120.
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gp120 digest, and L29 was observed as a very low
abundance ion in the mass spectrum of affinity-bound
peptides. These results clearly show that residue R is
missing from the C-terminus of gp120 and that K is only
present to a limited extent.
In the Lys-C experiments, peptides L17 and L2 (aa
3–15) were observed to bind to the antibody. The
peptides corresponding to the same regions of the
protein, however, were not observed in the Glu-C and
Asp-N experiments. When epitope extraction was car-
ried out with Glu-C, a minor peak corresponding to
S3 1 S4 (aa 18–34, m/z 3949) was observed to bind to
the antibody. Because the binding of these peptides L2,
L17, and S3 1 S4 were most prevalent in epitope
extraction experiments and these peptides were also
observed in the supernatant containing the unbound
peptides, the weak binding of these peptides to the
antibody may be attributed to a nonspecific binding.
The recent observations that a single antibody can
recognize more than one antigenic region, if structural
similarity or mimicry exists, may also be an explanation
for these results [32].
The absence of ions due to peptides corresponding to
L2 and L17 in the MALDI/MS spectra of the Glu-C and
Asp-N experiments may be attributable to lower sensi-
tivity of these peptides. The ions arising from peptides
L17 and L2 were the most abundant ions in the MALDI
spectrum of the Lys-C digest of free gp120 but the ions
arising from the corresponding Glu-C and Asp-N pep-
tides were less abundant or were completely sup-
pressed in the MALDI spectra of gp120 digested in
solution [33]. The Glu-C and Asp-N peptides containing
the same sequences of L17 could not be specifically
identified in the MALDI spectra of free gp120 digests
because of the potential glycosylation. The glycosylated
peptides in the free gp120 digest were observed as
broad ions, probably, due to the heterogeneity within
the carbohydrate moiety and multiple sodium adduct
formation [34]. However, intense ions of affinity bound
glycosylated peptides were observed in experiments
not pertinent to this study. The precise identification of
these peptides were not attempted as the specific gly-
cosylation pattern of gp120 from HIV-SF2 is not known.
Conclusion
By using a limited polyclonal antibody with a known
antigenic region as a model we have demonstrated that
the fine structure of continuous epitopes of gp120 can
be characterized either by epitope excision and/or
extraction followed by MALDI/MS characterization. It
should be noted, however, that the defined epitope in
the present example is not glycosylated. Although three
different enzymes were used in the present study, it is
possible to narrowly define an epitope recognized by a
monoclonal antibody with any one of the enzymes
combined with exopeptidase digestions.
Two separate studies have shown that sera of HIV
positive individuals contain antibodies that recognize
peptides similar to the peptide used in the present
study. A peptide SP22 (APTKAKRRVVQREKR) from
the C-terminus of gp120 has been identified as an
immunodominant region recognized by most of the
antibodies found in the sera of HIV positive individuals
[35]. A similar peptide, Env497 (TKAKRRVVQREKR),
has also been identified as the antigenic peptide recog-
nized by antibodies from sera of infected individuals
[36]. This study has also shown that antibodies recog-
nizing Env497 neutralize HIV at high concentrations.
An antibody recognizing the C-terminus of gp120 has
also been used in antigen capture enzyme-linked im-
munosorbent assay for cross competition analysis, to
determine the enhancement/inhibition of MAbs by the
binding of other MAbs [37]. The epitopes recognized by
these antibodies have, however, not been narrowly
defined.
We have identified residues RRVVQRE, which are
contained within the immunodominant regions identi-
fied in the abovementioned studies, as the major or
immunodominant epitope recognized by the polyclonal
antibody. The minor epitopes could be identified as
being contained in the sequences APTKAKRRVVQ,
APTKAKRRV, APTKAKRR, and RRVVQR. This as-
sumes that the ionization efficiencies of the various
peptides are relatively equal (but see [38]). The above
studies show that although the polyclonal antibody
used in this study is raised against a peptide antigen,
antibodies recognizing epitopes within this region can
be elicited by native gp120 and may be an important
component of the immune response to gp120.
Neutralizing antibodies in infected individuals have
been shown to recognize both linear and conforma-
tional epitopes [39, 40]. A complete characterization of
linear and conformational epitopes recognized by these
antibodies is essential to understand the mechanism
that inhibits viral infectivity. The approaches currently
available to map discontinuous epitopes are binding-
affinity analysis by using mutant proteins, NMR, and
x-ray crystallography of the antigen–antibody complex.
These methods, however, are limited by the availability
of mutants and by the large amount of antigen, the
difficulties in forming crystals, and by the long time
taken for the analysis.
The ability to characterize several affinity-bound
peptides simultaneously, as in the present study, indi-
cates that the technique should be valid for the deter-
mination of discontinuous epitopes. By combining ex-
opeptidase digestions with secondary and tertiary
structural information from the database and molecular
modeling, the discontinuous epitopes might be identi-
fied unambiguously.
In addition, these methodologies can also provide
tertiary structural informations on gp120 that can be
used in improving the structural model of gp120 [41].
This information is especially valuable for gp120 where
no x-ray crystallographic structure is available.
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